Johnson & Johnson (JNJ) Competitors & Peers
The 5 companies closest to Johnson & Johnson on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,231.94 | P/E 39.8RSI 61Cap 1.10 T |
| ABBV | Competitor | $247.97 | P/E 69.5RSI 50Cap 438.2 B |
| MRK | Peer | $130.92 | P/E 103.1RSI 60Cap 323.0 B |
| AZN | Peer | $161.91 | P/E 24.2RSI 40Cap 251.1 B |
| NVS | Peer | $156.79 | P/E 23.6RSI 55Cap 298.0 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- ZBHCompetitor
Zimmer Biomet competes with Johnson & Johnson's orthopedics franchise (DePuy Synthes) in hip, knee, trauma, and extremity implants.
Confirmed — SEC filing / public disclosuresec.gov ↗ - XGNSupplier
Own 10-K customer-concentration disclosure: JanssenSIMPONI = 12% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORSupplier
Cencora is JNJ's third-largest wholesale distributor, representing approximately 11.1% of consolidated gross revenues.
Confirmed — SEC filing / public disclosuresec.gov ↗ - SYKCompetitor
Johnson & Johnson MedTech competes with Stryker in orthopaedics (DePuy Synthes), spine, and surgical tools.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is JNJ's largest wholesale distributor, representing approximately 21.8% of consolidated gross revenues.
Confirmed — SEC filing / public disclosuresec.gov ↗ - ANIKSupplier
Own 10-Q customer-concentration disclosure: DepuySynthesMitekSportsMedicine = 44% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - VCYTSupplier
Own 10-Q customer-concentration disclosure: JohnsonAndJohnsonServicesIncJjsi = 13% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - HALOSupplier
Own 10-K customer-concentration disclosure: Janssen = 18% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MGNXSupplier
Own 10-K customer-concentration disclosure: JanssenBiotechInc = 19% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- ALKSCustomer
Alkermes receives substantial royalties from J&J for Invega Sustenna.
Model-inferred, unverified — treat as a lead, not evidence - IARTPartner
Integra acquired Acclarent, Inc. (an ENT medical device innovator) from Johnson & Johnson's Ethicon division for $280 million in cash in April 2024.
Model-inferred, unverified — treat as a lead, not evidence - ITCIMerger
JNJ acquired Intra-Cellular for $14.6B (closed 2025).
Model-inferred, unverified — treat as a lead, not evidence - ITCIPartner
JNJ acquired Intra-Cellular for $14.6B (closed 2025).
Model-inferred, unverified — treat as a lead, not evidence - GMABPartner
Genmab + JNJ co-developed Darzalex (daratumumab); royalty stream to Genmab.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
J&J competes with AbbVie in the immunology market (Stelara/Tremfya vs Skyrizi).
Model-inferred, unverified — treat as a lead, not evidence - SNNCompetitor
Smith & Nephew competes with JNJ's DePuy Synthes unit in orthopedic reconstructive implants, trauma care, and soft tissue repair.
Model-inferred, unverified — treat as a lead, not evidence - ARWRPartner
Arrowhead co-develops RNAi therapeutics for HBV with Janssen (J&J).
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal distributes J&J products.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora distributes J&J products.
Model-inferred, unverified — treat as a lead, not evidence - ISRGCompetitor
J&J Ottava soft-tissue robot (Phase II trials 2025) directly competes with da Vinci.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
J&J is a key pharmaceutical and medical device supplier to Cardinal Health's distribution network.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson distributes J&J pharmaceuticals.
Model-inferred, unverified — treat as a lead, not evidence - RGCCompetitor
Competes in ADHD treatment markets, where JNJ markets Concerta.
Model-inferred, unverified — treat as a lead, not evidence - WBASupplier
Walgreens dispenses J&J consumer health + Rx.
Model-inferred, unverified — treat as a lead, not evidence - CVSSupplier
CVS is among JNJ pharmacy customers.
Model-inferred, unverified — treat as a lead, not evidence - BHCCompetitor
Competes in specialty eye care and dermatology drug segments.
Model-inferred, unverified — treat as a lead, not evidence - IQVSupplier
J&J Innovative Medicine uses IQVIA across late-stage trials and real-world evidence.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
J&J uses Veeva Vault Quality + Regulatory across pharma and medtech.
Model-inferred, unverified — treat as a lead, not evidence